Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Another one bites the dust.
Durrant and crew will deliver!
Just caught HGEN on the CNBC ticker @ 13,60. It's going to be a good day.
Report: Moderna and Pfizer Vaccine Trial Participants Report Serious Side Effects
Five patients across the two studies apparently experienced chills, fever, and intense headaches.
https://www.fool.com/investing/2020/10/05/report-moderna-and-pfizer-vaccine-trial-participan/
FYI
Once Thought to Make COVID-19 Worse, ACE Inhibitors Now Tested as Therapeutic
WRITTEN BY: Carmen Leitch
MAY 01, 2020 3:42 PM PDT
SARS-CoV-2 is the virus that causes COVID-19, a pandemic illness. Researchers have learned that the virus can enter cells through a receptor called ACE2. Early on in the disease outbreak, scientists became concerned that certain drugs called ACE inhibitors may increase the chance of infection, or make an infection worse once it happened. Several new studies have shown, however, that those concerns were unfounded.
ACE inhibitors are sometimes prescribed to people that have high blood pressure. Angiotensin II is a molecule that can increase blood pressure by narrowing blood vessels. The level of angiotensin II is controlled by the angiotensin-converting enzyme (ACE), so if that enzyme is inhibited by a drug, there is less angiotensin II and blood pressure goes down.
In a study that included 12,594 individuals, there was no evidence of a link between the likelihood of a positive COVID-19 test and a number of blood pressure-reducing drugs: angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta blockers, or calcium channel blockers. There was also no connection between these drugs and a more severe infection, whether it would require a ventilator, intensive care, or result in death. The findings have been reported in the New England Journal of Medicine.
"With nearly half of American adults having high blood pressure, and heart disease patients more vulnerable to COVID-19, understanding the relationship between these commonly used medications and COVID-19 was a critical public health concern," said the lead study investigator Harmony Reynolds, M.D., associate director of the Cardiovascular Clinical Research Center at NYU Langone Health. "Our findings should reassure the medical community and patients about the continued use of these commonly prescribed medications, which prevent potentially severe heart events in their own right."
Incredibly, another new study is now determining whether these drugs may be of some benefit to COVID-19 patients. ACE is part of the renin-angiotensin-aldosterone system (RAAS), which controls blood pressure, and balances the levels of water and sodium in cells and the extracellular environment, ensuring healthy function.
"Our hypothesis is that ACE inhibitor drugs help keep the RAAS system in balance and functioning optimally," said the principal investigator of the study, Rohit Loomba, M.D., professor of medicine and director of the NAFLD Research Center at UC San Diego School of Medicine. "SARS infections create an imbalance, triggering feedback loops that promote inflammation and injury -- a vicious cycle of pathological consequences that wrack the lungs, heart and other organs, and kill."
Colorized scanning electron micrograph of a VERO E6 cell (purple) exhibiting elongated cell projections and signs of apoptosis, after infection with SARS-COV-2 virus particles (pink), which were isolated from a patient sample. Image captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. / Credit: NIAID
Loomba noted that there is another factor that is influencing COVID-19 infections in people that are taking ACE inhibitors. "Age appears to be the primary risk factor for COVID-19 and high blood pressure is quite prevalent in people over the age of 60," Loomba said.
Sources: AAAS/Eurekalert! via University of California - San Diego, NYU Langone Health / NYU School of Medicine, New England Journal of Medicine
https://www.labroots.com/trending/microbiology/17520/covid-19-worse-ace-inhibitors-tested-therapeutic
About the Author
Carmen Leitch
Experienced research scientist and technical expert with authorships on 28 peer-reviewed publications, traveler to over 60 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
Can someone provide a brief summary of what was talked about on the TC show last night? All my efforts to view the video are either blocked or removed. Thanks.
I agree with you, lots of unknowns. My primary concern which you touch on is drug supply. In Today's PR, Durrant mentioned the potential front line treatment (SOC?) of Lenz, so demand will be off the charts if that's the case. Sounds like the Chemistry, Manufacturing and Controls are going as planned so guess we wait to see. A good part of me feels like we got this.
Good data and save on the case report!
I noticed the completion date of 2023. But what caught my attention was the description.
Detailed Description:
If I had to guess the ACTT-3 trial would be the design and description that seems most appropriate to include BET.
https://clinicaltrials.gov/ct2/show/NCT04492475?term=Adaptive+COVID-19+Treatment+Trial+3&draw=2&rank=1
Thoughts appreciated.
Huge News on the ARDS patient today. I would imagine all organ failure(sepsis) type situations will be in play. SOC? We need LENZ NOW!
Serving up all the goodies today. This is great news! Check the buoy report, ground swell fast approaching.
Time to wax the board.
It appears to be a Lily trial sponsored by NIAID. Not sure if there's anything more to it. 10000 is a good amount of participants.
This trial makes me go hmmmm...
https://clinicaltrials.gov/ct2/show/NCT04501978
ACTIV-3: Therapeutics for Inpatients With COVID-19 (TICO)
Fezziwig2008 Wednesday, 08/05/20 03:00:28 PM
Re: JustAguy22 post# 12989 0
Post # of 18785
HGEN Targets GM CSF ligand not receptor - CEO made the points they this allies safe dosing over a very large range- due to added safety over Mav and other anti receptor agents. Leronlilumab May be safe but it’s Th1 CCR5 Target is far down the Cytokine chain and not as effective as Lenzilumab - which also influences Th1 plus other Targets (IL 6 TNFa etc).
This site may be useful, Knuckle.
https://www.phe.gov/about/sns/Pages/default.aspx
https://www.phe.gov/about/amcg/BARDA-BAA/Pages/default.aspx
Cheers!
The first real CRS company to market that I'm aware of was listed here this past Friday. That company went from $3 to 11 post EUA, currently 326mc. They've never really gotten the media attention, but that's nothing new for non-chosen small cap bio.
So what effect should a $300M cash infusion have on
our market cap going forward?
I would imagine they will concentrate on the company pipeline while working with our partners on drug developement, manufacturing and approvals. The shelf allows management three years to issue, so time is on our side which should lend to more favorable outcomes on our deals going forward. The confidence that exudes from management sends a strong signal to me that they will execute timely moves and capitalize on opporutnities as they present. So, I will thankfully leave that up to them.
Hope HGEN hits a grand slam and shorts get crushed!
I guess I dont get it.
FYI, I've not had a position in the other company for 5 months. Hopefully, HGEN can follow in the same footsteps and be successful. And, I do not believe in shorting stocks that are in the business of saving lives!
What a drift from the original subject. lol
Okay.
My recommendation for you, and all, is to go their website and read the patient registry and 'case of the week' studies. This is about saving lives.
But, sorry, no EUA for 100$.
Prone has more to do with elevating BP, imo. Have you ever taken your BP in prone position opposed to on your back? Huge difference. O2 concentration is better when laying on your left side given extra lobe (volume) on your right. Are you a doctor? If so, please correct me.
Yeah, isn't that sad, a US company that has to go outside its own country to get approval for their life saving products. They've been selling to the world for the past 7yrs. Only because of covid do they now have a shot for approval. Brazil just approved them for cytokine storm and other indications, add them to the global list.
CTSO mkt cap is 336m. This is a company whose established thier own manufacturing that runs 24/7, a global presence in 60+ countries and growing. 100$ EUA is a pipe dream for HGEN, imo. BO play is a better bet.
CTSO,which leads in cytokine storm treatments with 100,000+, got EUA on May 10. Their pps ran 300% prior to that approval then leveled off. Does Lenz follow the same pattern?
It's encouraging to see Humanigen getting some research coverage.
https://thedailychronicle.in/?s=humanigen
I agree. Margin trading becomes a handy tool for shorts as well.
Cytosorb gets nod in Brazil.
Knuckle,
This is a whopper! Seems a little fishy that Gottlieb mentioned this last month yet no coverage. He's on CNBC every F'n Morning! Oh boy, talk about getting ahead of the story(HGEN). The cat is out of the proverbial bag, imo. Strap up and let's get it on!
To our knodledge HGEN does not even have a expidited designation. Not good face for FDA! 21st Century Cures Act, hello?
try now
Broker assist?
Try to log out then back in. My HGEND orders were just outed. GL
Let trading begin!
Pre mkt ARCA 500 @ 10.44
http://archive.fast-edgar.com/20200918/AABEI22CZ222G9Z2222E2ZZZCLLGZNE25222/8A_Cert_HGEN.pdf
Float shares are free trading. Shares in the offering will be distributed to those who subscribed, under conditions agreed. imo.
Knuckle Sandwich.. Great News!!! Ring the Bell.
Time to strap in set your price now if you are buying. Shorters are licking their chops.